Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Vericiguat on Vascular Biology and Cardiovascular Performance in HFrEF
NCT05704478Phase 4Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vericiguat in heart failure with reduced ejection fraction (HFrEF), sponsored by University of Colorado Denver. Started Jan 2024; status: active, not recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05704478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704478.